The siRNA therapeutics market is expected to grow substantially from $12.7 billion in 2022 to $39.2 billion by 2029.

In an era characterized by information overload, effectively managing and utilizing vast amounts of biomedical data has become another pressing issue.

In recent years, a molecular target known as Claudin18.2 has emerged as a prominent target in the treatment of gastric cancer, pancreatic cancer, and various other solid tumors.

the Antibody-Drug Conjugates (ADCs) market has entered a new phase of rapid growth since 2019, maintaining an annual growth rate exceeding 30%.

Currently, only three CXCR4 (C-X-C motif chemokine receptor 4) antagonists have been approved globally: Plerixafor, Motixafortide, and Mavorixafor.

the siRNA therapeutics market is projected to grow substantially from $12.7 billion in 2023 to $39.2 billion by 2029.

According to a report by Yole Développement, the CRISPR technology market is projected to reach $5 billion by 2023.

The global stem cell therapy market was valued at $10–12 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 10–15%.

The application of AI technology in new drug development spans several critical stages, from compound synthesis to drug repurposing.

In 2023, the global market for AAV (Adeno-associated virus) therapies reached $1.5 billion, with projections suggesting growth to $22.3 billion by 2029.

AI-driven technological innovation not only enhances the targeting precision of siRNA but also paves new pathways for future gene therapies.

Recently,the Center for Drug Evaluation of the NMPA announced the acceptance of the investigational new drug (IND) application for Novartis's PIT565 injection.